SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the appointment of Patrick O'Connor, PhD, Vice President, Research, Michael J. LaBarre, PhD, Vice President, Product Development, and James E. Cartoni, Vice President, Legal.
"Halozyme is committed to attracting, developing, and retaining world- class talent. We are delighted that seasoned executives such as Patrick, Michael, and Jim have joined the team. Successfully recruiting executives of this caliber underscores our commitment to finding exceptional talent, and also reflects the high level of excitement Halozyme is generating in the biotech industry," said Jonathan Lim, MD, President and CEO of Halozyme Therapeutics. "Their broad collective experience in drug development, formulation, analytical methodology, manufacturing, and the legal aspects of biotechnology brings further breadth and depth to our leadership team. All three executives will work closely with our senior management to enable Halozyme to achieve its business objectives."
Patrick O'Connor's responsibilities will include leadership of
Halozyme's multiple biology and chemistry research programs. Dr. O'Connor
joins Halozyme from Ardea Biosciences where he was Senior Vice President
and Chief Scientific Officer. Prior to joining Ardea, Dr. O'Connor served
in various executive research positions at Pfizer Global Research &
Development and Agouron Pharmaceuticals (now Pfizer, Inc.) from 1998 to
2007. His last position with Pfizer as Vice President, Research Therapeutic
Area Head, Global Oncology, included responsibility for setting the overall
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved